12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

• Enveric Biosciences NASDAQ:ENVB shares moved upwards by 11.0% to $0.36 during Tuesday's after-market session. Enveric Biosciences's trading volume hit 1.3 million shares by close, accounting for 49.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $18.8 million.
• Bone Biologics NASDAQ:BBLG shares moved upwards by 10.85% to $2.45. The company's market cap stands at $25.3 million.
• Zosano Pharma NASDAQ:ZSAN stock moved upwards by 7.89% to $2.87. The market value of their outstanding shares is at $14.0 million.
• IMAC Holdings NASDAQ:IMAC shares moved upwards by 7.14% to $0.91. The market value of their outstanding shares is at $24.1 million. The company's, Q4 earnings came out 3 days ago.
• Cyclerion Therapeutics NASDAQ:CYCN stock moved upwards by 6.17% to $1.02. The market value of their outstanding shares is at $44.2 million.
• TherapeuticsMD NASDAQ:TXMD stock moved upwards by 5.62% to $0.28. Today's trading volume for this security ended up closing at 3.9 million shares, which is 56.3 percent of its average volume over the last 100 days. The company's market cap stands at $121.3 million.

Losers

• Humacyte NASDAQ:HUMA stock fell 8.1% to $6.8 during Tuesday's after-market session. The company's market cap stands at $700.4 million.
• LifeStance Health Gr NASDAQ:LFST stock fell 8.04% to $9.5. The market value of their outstanding shares is at $3.5 billion.
• DexCom NASDAQ:DXCM shares fell 7.45% to $455.01. The market value of their outstanding shares is at $44.6 billion.
• Ikena Oncology NASDAQ:IKNA shares fell 6.81% to $6.03. The company's market cap stands at $217.7 million.
• Acutus Medical NASDAQ:AFIB shares declined by 6.76% to $0.9. The company's market cap stands at $25.4 million.
• Achilles Therapeutics NASDAQ:ACHL stock declined by 6.62% to $2.4. The company's market cap stands at $93.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.